# **International Seminars in Surgical** Oncology



**Open Access** Research

# Intimal pulmonary artery sarcoma presenting as dyspnea: case report

Jeff M Hsing<sup>1</sup>, Snehal G Thakkar\*<sup>2</sup>, Ernest C Borden<sup>2</sup> and George T Budd<sup>2</sup>

Address: <sup>1</sup>Department of Internal Medicine, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA and <sup>2</sup>Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA

> Received: 17 May 2006 Accepted: 29 June 2007

Email: Jeff M Hsing - hsingj@ccf.org; Snehal G Thakkar\* - thakkas@ccg.org; Ernest C Borden - bordene@ccf.org; George T Budd - buddg@ccf.org

\* Corresponding author

Published: 29 June 2007

International Seminars in Surgical Oncology 2007, 4:14 doi:10.1186/1477-7800-4-14

This article is available from: http://www.issoonline.com/content/4/1/14

© 2007 Hsing et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### **Abstract**

Background: We report a case of pulmonary sarcoma which is a rare cause of the common symptom of dyspnea.

Case presentation: A fifty-one year old previously healthy male presented to the emergency room with complaints of dyspnea on exertion. A cardiac workup including an exercise stress test was negative but an echocardiography showed pulmonary stenosis. Cardiac MRI showed a large mass extending from the pulmonic valve to both the right and left pulmonary arteries suggestive of sarcoma. A complete resection and repair of the pulmonary artery was done and adjuvant chemotherapy with doxorubicin and ifosfamide was recommended. The patient is currently disease free after eighteen months.

**Conclusion:** Pulmonary artery sarcomas are a difficult diagnosis. The diagnosis may remain elusive for some time until the proper imaging techniques are utilized to make a diagnosis. Earlier and accurate diagnosis may lead to earlier interventions and improve survival.

## **Background**

Dyspnea is a frequent presentation to the emergency room. The differential diagnosis is extensive and often the diagnosis remains obscure. Pulmonary sarcomas are a rare cause of dyspnea, but do present as such and are often initially misdiagnosed.

# **Case Presentation**

A 51 year old previously healthy male presented to the emergency room with complaints of dyspnea, chest pain and palpitations while playing tennis. This was the second time over the last month that he experienced some palpitations and dyspnea with exertion. Previously, the patient was ruled out for a myocardial infarction and had a stress

echocardiogram which showed mild/moderate pulmonic stenosis, normal right ventricle, and thickened pulmonic valve with doming, but otherwise normal stress test. He was sent home from the emergency room with follow-up with his primary care physician and cardiologist. His cardiologist ordered a cardiac MRI to further evaluate the pulmonic valve. The MRI revealed a large mass starting near the pulmonic valve and extending into the main pulmonary artery and 4 cm into the right pulmonary artery and 3 cm into the left pulmonary artery (Fig 1). The MRI findings were suspicious for a pulmonary artery sarcoma. The patient was admitted into the hospital for further evaluation of the mass. Although the patient's vital signs were stable with normal oxygen saturation he was started

on heparin due to suspicion of a thromboembolism. CT scan of the chest was done which showed the large pulmonary artery mass and 2 small 9 mm nodular densities of the right lung without lymphadenopathy (Fig 2). PET-FDG showed uptake in the pulmonary artery trunk, but the 2 nodules did not show abnormal FDG uptake. Cardiothoracic surgery was consulted and the pulmonary artery mass and 2 lung wedge resections were completely excised. Frozen section evaluation was consistent with sarcoma.

Gross pathology showed a large intimal sarcoma filling the pulmonary artery (Fig 3). It infiltrated the arterial media without extension into the adventitia. The neoplasm consisted of spindled and stellate-shaped cells deposited in variably myxoid stroma (Fig 4). The 2 lung wedges were positive for metastatic sarcoma.

The patient tolerated the surgery well and was discharged with oncology follow-up as an outpatient. Adjuvant chemotherapy with doxorubicin and ifosfamide was initiated soon thereafter. Eighteen months later and after 7



Figure 1
Cardiac MRI showing the sarcoma arising from right ventricle outflow tract to both the right and left pulmonary artery.




Figure 2
CT scan showing extensive involvement of the main pulmonary artery and into the right trunk.

cycles of chemotherapy, he continues to remain disease free by imaging.

#### Conclusion

Sarcoma of the great vessels are rare and are usually found in the aorta (most often abdominal), inferior vena cava, or pulmonary artery. Typically, these sarcomas are rare and highly lethal that previously were diagnosed during surgery or autopsy. Patients typically present between the ages of 22 and 81 with female sex predominance. The prognosis is poor with a mean survival of 12 months after onset of symptoms and 1 and 2 year survival rates of 22% and 7% respectively[1]. The presentation usually corresponds to the location of the sarcoma. In the case of a pulmonary artery sarcoma dyspnea, chest pain, cough and hemoptysis are the most frequent complaints. A common error involves diagnosing a pulmonary thromboembolism and treating it as such. There have been a number of case reports and several literature reviews discussing the findings of a pulmonary artery sarcoma. Older case reports usually only made the correct diagnosis during surgery or autopsy and only after a prolonged period of symptoms[2]. More recent advances in imaging technology with multi-slice CT and MRI have enabled better tissue and anatomy characterization [3-5]. This has enabled making the correct diagnosis earlier and differentiating it from other pulmonary vascular pathologies, namely thromboembolism. Quicker diagnosis allows earlier potential curative treatment with surgical resection and




Figure 3
Gross pathology of the sarcoma invading the pulmonary artery.

adjuvant chemotherapy with or without radiation. At present it is unclear whether earlier diagnosis followed by earlier initiation of treatment leads to improved overall survival.

The World Health Organization (WHO) classify sarcomas on the basis of hematoxylin-eosin, Masson-trichrome, and periodic acid-Schiff stained sections[6]. Sarcomas of the great vessels are usually one of three types: angiosarcoma, leiomyosarcoma, or intimal sarcoma. Leiomyosarcomas arise from the smooth muscle, are spindle cell

shaped and stain for desmin and actin. Angiosarcomas arise from the endothelial cells of blood vessels and stain for filament proteins vimentin, factor VIII, and CD34. Sarcomas that don't fit into one of the other categories are termed "intimal." The histologic and immunohistochemical findings are summarized in Table 1. Pulmonary artery sarcomas often arise from the intimal layer of the pulmonary trunk and spread either antegrade into the pulmonary artery branches or retrograde into the pulmonic valve and right ventricle[7]. Metastases are usually found in the lungs, but other sites include kidney, brain, lymph node and skin[6].

The mainstay of treatment for sarcoma is surgical resection as this remains the only potentially curative modality. Adjuvant radiation and chemotherapy can be considered following surgical excision although their role remains undefined. An approximate 20% response rate can be expected with a combination chemotherapy regimen involving an anthracycline and an alkylating agent, however, the value of this regimen in the adjuvant setting for pulmonary artery sarcoma is unclear [8,9].

#### **Abbreviations**

CT - Computed Tomography

MRI - Magnetic Resonance Imaging

PET - Positron Emission Tomography

FDG - Fluorodeoxyglucose




Figure 4
Low field and high field microscopic findings showing spindle cells with hyperchromatic nuclei in myxoid background.

Table I: Summary of the common types of sarcomas of the great vessels

Histologic Type	Cell of Origin	Histologic feature	Immunohistochemical
Angiosarcoma	Blood vessels	Endothelial cells	Vimentin, Factor VIII, CD 34
Leiomyosarcoma	Smooth muscle	Spindle shape	Desmin, Actin
Intimal	Unknown	Undifferentiated cells	Varies

### **Competing interests**

The author(s) declare that they have no competing inter-

# **Acknowledgements**

Written consent was obtained from the patient for publication.

#### References

- Govender D, Pillay SV: Right pulmonary artery sarcoma. Pathology 2001, 33:243-245.
- Johansson L, Carlen B: Sarcoma of the pulmonary artery: report of four cases with electron microscopic and immunohistochemical examinations, and review of the literature. Virchows Arch 1994, 424:217-224.
- Dennie CJ, Veinot JP, McCormack DG, Rubens FD: Intimal sarcoma of the pulmonary arteries seen as a mosaic pattern of lung attenuation on high-resolution CT. AJR Am J Roentgenol 2002, 178:1208-1210.
- Choi EY, Yoon YW, Kwon HM, Kim D, Park BE, Hong YS, Koo JS, Kim TH, Kim HS: A case of pulmonary artery intimal sarcoma diagnosed with multislice CT scan with 3D reconstruction. Yonsei Med J 2004, 45:547-551.
- Weinreb JC, Davis SD, Berkmen YM, Isom W, Naidich DP: Pulmonary artery sarcoma: evaluation using Gd-DTPA. J Comput Assist Tomogr 1990, 14:647-649.
- Burke AP, Virmani R: Sarcomas of the great vessels. A clinicopathologic study. Cancer 1993, 71:1761-1773. Raaf HN, Raaf JH: Sarcomas related to the heart and vascula-
- 7. ture. Semin Surg Oncol 1994, 10:374-382.
- Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654.
- Keohan ML, Taub RN: Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol 1997, **24:**572-579.

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- · yours you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing\_adv.asp

